There was good news about one of its less-popular products. On reports of a previously undetected potential health benefit of CBD, investors piled into Curaleaf stock and pushed its value nearly 10% higher on the day. That news is encouraging, not only because of the potential new use for CBD to help treat a stubborn condition. The study was partially funded by the federal government's National Institute on Alcohol Abuse and Alcoholism, which might at least slightly tilt officialdom's sentiment on marijuana ...

格隆汇8月21日丨莱茵生物(002166.SZ)在投资者互动平台表示，公司拥有一定量的CBD存货，美国印州 工厂具备工业大麻提取物的生产能力，可及时响应市场需求。 ...

Core Viewpoint - High Tide Inc. has secured a $30 million convertible debt loan from a subsidiary of Cronos Group to fund future acquisitions and expand its cannabis retail operations in Canada, aiming to grow its store network beyond 300 locations [1][2][3]. Group 1: Loan Agreement Details - The Junior Secured Loan has a principal amount of $30 million, secured by a third priority lien on certain assets of High Tide, and bears an interest rate of 4% per annum [4]. - The loan has a 5-year term and can be repaid at any time without penalty, with the option for Cronos to convert the loan into common shares at a price of $4.20 per share [4]. - Cronos also received a warrant to purchase up to 3,836,317 common shares at an exercise price of $3.91 per share, representing a 25% premium to the 30-day volume weighted average price [5]. Group 2: Company Growth and Strategy - High Tide aims to utilize the working capital from the loan to enhance its business operations and expand its retail presence, reinforcing its position as a key player in the legal cannabis ecosystem [2][3]. - The company has been recognized as one of Canada's Top Growing Companies and ranked number one in the retail category on the Financial Times list of Americas' Fastest Growing Companies for 2023 [11]. - High Tide operates the largest cannabis retail chain in Canada, Canna Cabana, with 202 locations and continues to innovate in retail technology and consumer products [7][8]. Group 3: Industry Context - The investment from Cronos reflects a belief in the importance of a competitive retail environment that benefits producers, retailers, and consumers alike [3]. - High Tide's integrated operations across various components of cannabis, including retail, consumption accessories, and CBD, position it well within the growing cannabis market [7][10].

The Kings Of CBD Are Now Cooking Up Plans To Make Billion-Dollar Meds From Cannabis And Mushrooms https://t.co/xNmG4gYtFY (Photo: Charlotte’s Web) https://t.co/PaN4YyPjAz ...

Group 1: Research and Development - The company has 4 specialized pharmaceutical research institutions and 1 postdoctoral workstation, with a research team of approximately 200 people, accounting for about 20% of total employees. In 2024, R&D investment is expected to be 16.76% of sales revenue [1] - The WYY project is a novel compound with over 20 intellectual property applications globally, demonstrating superior efficacy and safety compared to competitors in animal studies. It is currently in the preclinical research stage, with an IND application planned for submission within the year [2] Group 2: Project Updates - The Wuhan Psychological Rehabilitation Hospital project received its medical institution practice license by the end of December 2024, aiming to operate as a tertiary specialized hospital [4] - The company is advancing the production line for recombinant collagen, with stable production processes meeting industry standards, and is preparing for large-scale production [6] Group 3: Market and Financial Insights - The gross profit margin for the company's main product, "A Le," has remained around 60% despite the impact of centralized procurement policies [8] - The company is considering external licensing for the WYY project based on clinical trial progress and commercialization conditions [3] Group 4: Future Developments - The company is focusing on developing CBD for treating pulmonary arterial hypertension, with a significant unmet market demand, as there are approximately 12 million patients in China [7][8] - VGX-3100, a key project of a major associate company, is undergoing phase III clinical trials for HPV-related cervical lesions, with plans to complete participant enrollment by 2025 [8]